Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Leukemia
•
AML
•
Hematology
With the recent approval of quizartinib, what is your preferred first-line FLT3 inhibitor in combination with chemotherapy for a fit AML patient with a FLT3-ITD mutation?
Related Questions
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
For AML patients, when do you stop antiinfective agents?
In a patient with tp53 mutated AML which has been refractory to Van+Aza and FLAG and in a center with limited clinical trial options; what treatment would you offer this patient?
What induction would you choose for a healthy 65 year old with prior chemo/RT for H&N cancer 2 years ago, now with FLT3-ITD+ (0.25) and inv(16) AML?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
How would you manage an early isolated CNS relapse in a pediatric patient with Ph positive ALL?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
